Denial Overturn Rates: What the Data Says About When Appeals Succeed

Overturn rates are the closest thing denial management has to a direct performance indicator. They measure what the appeals process is producing — not how many appeals were filed, but how many came back in the hospital's favor. The difference between a 40% overturn rate and a 70% overturn rate, across a denial inventory of any significant size, is millions of dollars. 

The data on overturn rates is less uniform than revenue cycle leaders might expect. National averages obscure significant variation by denial type, payer, and appeal level. Understanding that variation is the starting point for knowing where to invest appeal resources and where the returns are highest. 

For a broader overview of denial management strategies, visit our Denial Management in Healthcare Guide.

The Baseline Numbers 

Industry benchmarks for denial overturn rates vary depending on methodology and population studied. HFMA's revenue cycle benchmarking data places average overturn rates for appealed denials in the 40–60% range for standard commercial denials, with significant variation based on denial category and appeal quality. Clinical denials — medical necessity, level-of-care, DRG downgrade — tend to have lower average overturn rates when appeals are handled by generalist billing staff and higher rates when handled by clinical specialists. 

The American Hospital Association has documented that a meaningful share of denied claims that go to appeal are ultimately overturned — suggesting that a substantial portion of payer denials are, in the AHA's characterization, inappropriate. Many hospitals are writing off claims that could be recovered; the appeal process simply isn't reaching them. 

Where Overturn Rates Are Highest 

Technical and administrative denials generally have the highest overturn rates when worked correctly. These are denials that resulted from correctable errors — missing information, billing discrepancies, authorization numbers that exist but weren't included. When the correction is made and the claim is resubmitted or a simple appeal is filed, overturn rates can approach 80–90% for well-managed programs. 

Clinical denials are more variable. Medical necessity denials have lower average overturn rates than administrative denials, but they're not uniformly difficult to overturn. Overturn rates on clinical appeals depend heavily on: 

• The quality of the appeal — whether it specifically addresses the payer's criteria and connects the patient's clinical documentation to those criteria 

• The expertise of the reviewer — licensed clinicians with payer policy knowledge consistently outperform generalist billing staff on clinical appeals 

• The payer's historical behavior — some payers have higher overturn rates on appeal than others, a pattern that experienced denial management programs track and factor into strategy 

• The denial category — DRG downgrades and level-of-care denials tend to have different overturn profiles than straight medical necessity denials 

The Payer Variable 

Overturn rates vary significantly by payer. Commercial payers, Medicare Advantage plans, and Medicaid managed care organizations have meaningfully different overturn profiles — both at the claim type level and across appeal levels. A Medicare Advantage plan that denies medical necessity at a high rate but overturns 65% of well-constructed appeals represents a different operational challenge than a commercial plan that denies less but overturns a lower share of appeals. 

Organizations that track overturn rates by payer accumulate intelligence that changes their approach. Payers with high overturn rates may warrant more aggressive appeal investment. Payers with low overturn rates on specific denial types may warrant earlier escalation to external review or regulatory complaint pathways. 

The Kaiser Family Foundation's research on Medicare Advantage denial appeals found that a substantial proportion of denied claims that were appealed were ultimately overturned — indicating both that initial denial rates are inflated relative to actual non-covered care and that appeals programs produce material recoveries when they reach the right cases. 

The Multi-Level Appeal Curve 

Overturn rates also vary by appeal level. First-level internal appeals — the initial formal response to a denial — have the broadest variation, from very high overturn rates on administrative denials to lower rates on clinical denials. Second-level appeals, when available, typically have lower overturn rates because the easier cases were resolved at level one. 

External independent review, available for many plan types under state insurance laws and ACA provisions, has an interesting overturn rate profile. Because these reviews are conducted by clinicians independent of the payer, they can produce higher overturn rates than internal second-level appeals for certain clinical denial categories. Tracking cases through to external review, where available and justified, is a capability that many denial programs don't fully utilize. 

What the Data Says About Appeal Quality 

Across the denial categories and payer types, one variable consistently predicts overturn rates more than any other: appeal quality. The argument in the appeal letter, the documentation supporting it, and the policy citations grounding it determine whether a reviewer has the material needed to make a favorable determination. 

Generic appeals — letters that recite the clinical course without specifically connecting it to payer criteria — perform significantly worse than appeals that directly address the denial rationale with evidence-based arguments. The performance gap between the two approaches is the operational explanation for why specialist-led programs consistently outperform generalist billing teams on overturn rates. 

Revecore's documented 74% average overturn rate across its client base reflects what happens when clinical expertise, payer-specific policy knowledge, and AI-assisted record review are combined in a structured appeal process — rather than treating appeals as a volume exercise.